Dr. Reddy's Laboratories rises on entering into patent licensing agreement with Takeda Pharmaceutical
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Dr. Reddy's Laboratories is currently trading at Rs. 6680.00, up by 14.90 points or 0.22% from its previous closing of Rs. 6665.10 on the BSE.
The scrip opened at Rs. 6714.55 and has touched a high and low of Rs. 6714.55 and Rs. 6635.00 respectively. So far 737 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6882.70 on 15-Jul-2024 and a 52 week low of Rs. 5,212.10 on 30-Oct-2023.
Last one week high and low of the scrip stood at Rs. 6882.70 and Rs. 6592.40 respectively. The current market cap of the company is Rs. 111231.20 crore.
The promoters holding in the company stood at 26.65%, while Institutions and Non-Institutions held 48.40% and 10.36% respectively.
Dr. Reddy’s Laboratories has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company (Takeda) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONO to be available in two strengths, 10mg and 20mg.
Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
